Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. For more information, please contact Ashley Powell, (650) 724 - 3308. Among metastatic tumors, those that were HER2+ had better survival than other subtypes. Second Opinions From Medical Oncologists for Early-Stage Breast Cancer Prevalence, Correlates, and Consequences. Non-melanoma skin cancer (NMSC), the most prevalent cancer in the US,(1) has been associated with increased risk of non-cutaneous malignancies, including breast cancer, lung cancer, and lymphoma. Individuals with a single functional copy of the BRCA2 tumor suppressor have elevated risks for breast, ovarian, and other solid tumor malignancies. Candidate polygenic risk scores (PRSs) as predictors of personal breast cancer history were developed through multivariable logistic regression models adjusted for age, cancer history, and ancestry. Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative Compared to non-Hispanic White women, Korean [odds ratio (OR) = 1.8, 95% confidence interval (CI) = 1.5-2.2], Filipina (OR = 1.3, 95% CI = 1.2-1.5), Vietnamese (OR = 1.3, 95% CI = 1.1-1.6), and Chinese (OR = 1.1, 95% CI = 1.0-1.3) women had a significantly increased risk of being diagnosed with HER2-positive breast cancer subtypes after adjusting for age, stage, grade, socioeconomic status, histology, diagnosis year, nativity, and hospital ownership status. Among the three breast cancer types (hormone receptor-positive or human epidermal growth factor receptor 2 [HER2]-negative, HER2-positive, and triple-negative), there was no difference in CCPD. The most effective single intervention for BRCA1 mutation carriers is PO at age 40, yielding a 15% absolute survival gain; for BRCA2 mutation carriers, the most effective single intervention is PM, yielding a 7% survival gain if performed at age 40 years. Evidence-based guidelines recommend cascade genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for early detection and prevention of cancer. Surveys were sent approximately 2 months after surgery. Data on surgical decisions, motivations for those decisions, and knowledge were included in the analysis. However, he is an expert when it comes to his married life, wife and even children. For eight hypothetical cohorts of 100,000 persons defined by race/ethnicity and sex, we estimated cancer-related deaths if cancers diagnosed at stage IV were detected earlier, by assigning them outcomes of earlier stages.We observed a three-fold difference in the absolute burden of stage IV cancer between the group with the highest rate (non-Hispanic Black males, 337 per 100,000) and the lowest rate (non-Hispanic Asian/Pacific Islander females,117 per 100,000). To reduce the barrier of testing, a multiplex SNaPshot genotyping panel that targeted 25 ChineseBRCA1/2mutation hotspots was developed, and its feasibility was evaluated in a local cohort of 441 breast and 155 ovarian cancer patients. To examine whether interpersonal aspects of patient-clinician interactions, such as patient-perceived medical discrimination, clinician mistrust, and treatment decision-making contribute to racial/ethnic/educational disparities in breast cancer care.A telephone interview was administered to 542 Asian/Pacific Islander (API), Black, Hispanic, and White women identified through the Greater Bay Area Cancer Registry, ages 20 and older diagnosed with a first primary invasive breast cancer. Early life and education [ edit] The rate of final lumpectomy increased by 13% from 2013 to 2015, accompanied by a decrease in unilateral and bilateral mastectomy (P=.002). The authors described responses from approximately 73% of surgeons (370 surgeons), 61% of medical oncologists (306 medical oncologists), 67% of radiation oncologists (169 radiation oncologists), and 68% of patients (2502 patients).Approximately one-half (50.9%) of responding medical oncologists reported that someone in their practice often or always discusses financial burden with patients, as did 15.6% of surgeons and 43.2% of radiation oncologists. The app was developed incorporating quality-of-life surveys and symptom reporting, as well as resources on home survivor care. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery Thomas Kurian is an Indian-American business executive and Chief Executive Officer of Google Cloud since 2019. Factors that encouraged testing included relatives' cancer risk (75%; 95% CI, 73% to 78%), clinicians' recommendations (68%; 95% CI, 66% to 71%), and potential treatment implications (67%; 95% CI, 64% to 69%). Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., Koff, R., Chun, N. M., Rowe-Teeter, C., Lebensohn, A. P., Levonian, P., Lowstuter, K., Partynski, K., Hong, C., Mills, M. A., Petrovchich, I., Ma, C. S., Hartman, A. R., Allen, B., Wenstrup, R. J., Lancaster, J. M., Brown, K., Kidd, J., Evans, B., Mukherjee, B., McDonnell, K. J., Ladabaum, U., Ford, J. M., Gruber, S. B. We extracted individual-level data on chemotherapy administration from the electronic medical records of Kaiser Permanente Northern California (KPNC), a pre-paid integrated healthcare system serving 29 % of the local population. Results are moderately sensitive to variation in breast cancer survival rates and trastuzumab cost, and less sensitive to variations in cardiac toxicity.AT has an ICER comparable to those for other widely used interventions. A., Schackmann, E. A., Wapnir, I., Carlson, R. W., Sparano, J. Notably, failing to impute cases with missing receptor status leads to overestimation of survival because those with missing receptor status tend to have worse prognostic features. Validation studies with PLCO and EPIC showed consistent results. Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W. Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? These results may reassure newly diagnosed patients and longer follow-up is ongoing. View details for DOI 10.1200/JCO.21.00651. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. All patients underwent comprehensive BRCA1/2 genotyping. Impact:Given the growing number of breast cancer survivors worldwide, we need to better understand how comorbidities may adversely affect treatment decisions and ultimately outcome. Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., Kurian, A. W. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. National guidelines and peer-reviewed published literature were used to recommend that women with dense breast tissue at screening mammography follow supplemental screening guidelines based on breast cancer risk assessment. The independent but multiplicative associations of weight and familial risk suggest that, in terms of absolute breast cancer risk, the association with weight is more important the greater a woman's underlying familial risk. Mean age was 34 years; 66% were BRCA1 mutation carriers and 34% were BRCA2 mutation carriers. All statistical tests were 2-sided. Exploratory analyses, including simulation of a protective single-nucleotide polymorphism (SNP), rs140068132 at 6q25, were performed.During follow-up (median 18.9 years, maximum 23.4 years), 6783 breast cancer cases occurred among 90,967 women. Geczik, A. M., Ferris, J. S., Terry, M. B., Andrulis, I. L., Buys, S. S., Daly, M. B., Hopper, J. L., John, E. M., Kurian, A. W., Southey, M. C., Liao, Y., Genkinger, J. M. Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment. Furthermore, a multigene signature of the parenchymal imaging feature was built in a training cohort (n = 126), and its prognostic relevance was evaluated in two independent cohorts (n = 879 and 159). Thomas Kurian, chief executive officer of Google Cloud, at the company's campus in Sunnyvale, California (Bloomberg) Thomas Kurian's changes have given momentum to Google Cloud and prompted . View details for DOI 10.1158/1538-7755.DISP18-IA50, View details for DOI 10.1007/s12609-020-00354-3. This study aimed to examine the association between mindsets-established, but mutable beliefs that a person holds-and health-related quality of life in survivors of breast and gynecologic cancer.A cross-sectional survey study was conducted with breast and gynecologic cancer survivors. A minority of tested patients reported substantial cancer worry after treatment: 11.1% (n = 130) reported higher impact of cancer worry, and 15.1% (n = 162) reported a high frequency of cancer worry (worrying often or almost always) in the past month. In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. For ER-/PR- disease, BC-specific mortality did not differ by race/ethnicity and associations of race/ethnicity with BC-specific mortality varied only by neighborhood SES among African American women.Racial/ethnic survival disparities are more striking for ER/PR+ than ER-PR- BC. The primary outcome was the number of relatives who ordered genetic testing.One hundred twenty-five of 277 patients completed surveys (45.2%). Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P=.29). A., Trentham-Dietz, A. n., Vachon, C. M., Weinberg, C. n., Yao, S. n., Ziogas, A. n., Weitzel, J. N., Goldgar, D. E., Domchek, S. M., Nathanson, K. L., Kraft, P. n., Polley, E. C., Couch, F. J. Karimi, Y. H., Kurian, A. W., Blayney, D. W., Banerjee, I. Half of average-risk patients with VUS undergo BLM, suggesting a limited understanding of results that some surgeons share. Approximately 5%-10% of breast cancers are due to genetic predisposition caused by germline mutations; the most commonly tested genes are BRCA1 and BRCA2 mutations. In the free testing arm, 20 of 56 eligible patients participated (35.7% of eligible respondents) and they invited 28 relatives: 12 relatives enrolled and 10 ordered testing. Lebensohn, A. P., Kingham, K. E., Chun, N. M., Kurian, A. W. A Time to Decide: Patient Perspectives on Breast Cancer Treatment Decision Making. Alison Wagonfeld. Pampady is currently well-known for its engineering college . While incidence rates of breast cancer molecular subtypes are well documented, effects of molecular subtypes on breast cancer-specific survival using largest population coverage to date are unknown in the U.S.Using SEER (Surveillance, Epidemiology and End Results) cancer registry data, we assessed survival after breast cancer diagnosis among women diagnosed during 2010-2013 and followed through 12/31/2014. Using multivariable Cox proportional hazards regression, we estimated hazards ratios (HR) and 95% confidence intervals (CI) for overall and breast cancer-specific mortality associated with previous cancer, diabetes, high blood pressure (HBP), and myocardial infarction (MI). Meta-analyses were conducted to combine the results from these two datasets.Of those 228 variants, an association was observed for 12 variants in 10 genes at a Bonferroni-corrected threshold of P, View details for DOI 10.1016/j.ebiom.2019.09.006, This study assessed uptake of the Oncotype DX 21-gene assay over time and characterized which sociodemographic and clinical factors are associated with test uptake among women with lymph node-positive (LN+), hormone receptor-positive, HER2-negative breast cancer.Invasive breast cancer cases diagnosed in 2010 through 2013 were included from a SEER database linked to 21-gene assay results performed at Genomic Health's Clinical Laboratory. Lnning, P. E., Nikolaienko, O., Pan, K., Kurian, A. W., Eikesdal, H. P., Pettinger, M., Anderson, G. L., Prentice, R. L., Chlebowski, R. T., Knappskog, S. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer. Our study is a step toward systematic temporal research of coverage for precision medicine, which will inform policy and affordability assessments. A., Chung, W. K., Milne, R. L., Whittemore, A. S., Buchsbaum, R. n., Liao, Y. n., Zeinomar, N. n., Dite, G. S., Southey, M. C., Goldgar, D. n., Giles, G. G., Kurian, A. W., Andrulis, I. L., John, E. M., Daly, M. B., Buys, S. S., Phillips, K. A., Hopper, J. L., Terry, M. B. A., Giles, G. G., Grip, M., Gunel, P., Gndert, M., Hahnen, E., Haiman, C. A., Hkansson, N., Hall, P., Hamann, U., Hart, S. N., Hartikainen, J. M., Hartmann, A., He, W., Hooning, M. J., Hoppe, R., Hopper, J. L., Howell, A., Hunter, D. J., Jager, A., Jakubowska, A., Janni, W., John, E. M., Jung, A. Y., Kaaks, R., Keupers, M., Kitahara, C. M., Koutros, S., Kraft, P., Kristensen, V. N., Kurian, A. W., Lacey, J. V., Lambrechts, D., Le Marchand, L., Lindblom, A., Linet, M., Luben, R. N., Lubiski, J., Lush, M., Mannermaa, A., Manoochehri, M., Margolin, S., Martens, J. W., Martinez, M. E., Mavroudis, D., Michailidou, K., Milne, R. L., Mulligan, A. M., Muranen, T. A., Nevanlinna, H., Newman, W. G., Nielsen, S. F., Nordestgaard, B. G., Olshan, A. F., Olsson, H., Orr, N., Park-Simon, T. W., Patel, A. V., Peissel, B., Peterlongo, P., Plaseska-Karanfilska, D., Prajzendanc, K., Prentice, R., Presneau, N., Rack, B., Rennert, G., Rennert, H. S., Rhenius, V., Romero, A., Roylance, R., Ruebner, M., Saloustros, E., Sawyer, E. J., Schmutzler, R. K., Schneeweiss, A., Scott, C., Shah, M., Smichkoska, S., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Teras, L. R., Terry, M. B., Tollenaar, R. A., Tomlinson, I., Troester, M. A., Truong, T., Vachon, C. M., Wang, Q., Hurson, A. N., Winqvist, R., Wolk, A., Ziogas, A., Brauch, H., Garca-Closas, M., Pharoah, P. D., Easton, D. F., Chenevix-Trench, G., Schmidt, M. K. Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. Our findings suggest that physical activity is beneficial for overall survival regardless of race/ethnicity. The changes in breast cancer incidence across the pandemic did not vary by demographic factors. View details for Web of Science ID 000236796400112. Overall survival and time to next treatment were evaluated. Clinical data and pathologic characteristics were collected.BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. Lin, C. Y., Vennam, S. n., Purington, N. n., Lin, E. n., Varma, S. n., Han, S. n., Desa, M. n., Seto, T. n., Wang, N. J., Stehr, H. n., Troxell, M. L., Kurian, A. W., West, R. B. Chromatin Remodeling in Response to BRCA2-Crisis. Stanford is currently not accepting patients for this trial. Gallagher, S., Hughes, E., Kurian, A. W., Domchek, S. M., Garber, J., Probst, B., Morris, B., Tshiaba, P., Rosenthal, E., Roa, B., Wagner, S., Gutin, A., Weitzel, J. N., Lanchbury, J., Robson, M. E. Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site. Hormone therapy using Confirmatory controlled trials are warranted. Among African American women, BC-specific mortality was higher among those treated at non-accredited hospitals (HR 1.57, CI 1.21-2.04) and those from lower SES neighborhoods (HR 1.48, CI 1.16-1.88) compared to NHW women without these characteristics. B., Eliassen, A. H., Fasching, P. A., Flyger, H., Gago-Dominguez, M., Garca-Closas, M., Garca-Senz, J. These chromatin alterations are reflected in transcriptional profiles of pre-malignant tissues from BRCA2 carriers and, therefore, may reflect naturalsteps in human disease. This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation-associated breast cancer.This single-arm phase II study enrolled patients with stage I to IIIA (T 1 cm) estrogen receptor-negative ( 5%), progesterone receptor-negative ( 5%), and human epidermal growth factor receptor 2-negative or BRCA1/2 mutation-associated breast cancer. Lifetime risk of triple-negative breast cancer is highest in black women (1.98%, 1.80-2.17%), compared to 0.77% (0.67-0.88%) for Asians, 1.04% (0.96-1.13%) for Hispanics and 1.25% (1.20-1.30%) for whites. Blayney, D. W., Seto, T., Hoang, N., Lindquist, C., Kurian, A. W. Impact of COVID-19 on breast cancer care at a Bay Area academic center. Katz, S. J., Ward, K. C., Hamilton, A. S., Abrahamse, P. n., Hawley, S. T., Kurian, A. W. Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer. Association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women. Risk-reducing salpingo-oophorectomy was associated with a reduced risk of breast cancer for BRCA1 and BRCA2 pathogenic variant carriers within 5 years after surgery (hazard ratios [HRs], 0.28 [95% CI,0.10-0.63] and 0.19 [95% CI, 0.06-0.71], respectively), whereas the corresponding HRs were weaker after 5 years postsurgery (HRs, 0.64 [95% CI,0.38-0.97] and 0.99 [95% CI; 0.84-1.00], respectively). Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Lowstuter, K., Hartman, A., Allen, B., Kingham, K., Koff, R., Rowe-Teeter, C., Chun, N. M., Mills, M., Petrovchich, I., Hong, C., Kidd, J., McDonnell, K., Ladabaum, U., Ford, J. M., Gruber, S. B. This study aims to investigate the association between statin use and all-cancer survival in a prospective cohort of postmenopausal women, using data from the Women's Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT).The WHI study enrolled women aged 50-79 years from 1993 to 1998 at 40 US clinical centres. A., Teras, L. R., Terry, M. B., Tomlinson, I., Troester, M. A., Truong, T., Vachon, C. M., Wendt, C., Winqvist, R., Wolk, A., Yang, X. R., Zheng, W., Ziogas, A., Simard, J., Dunning, A. M., Pharoah, P. D., Easton, D. F. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. The 86-SNV score was associated with breast cancer risk in each of the carrier populations (P, View details for DOI 10.1001/jamanetworkopen.2020.8501. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types. Screening mammography has contributed to a significant increase in the diagnosis of ductal carcinoma in situ (DCIS), raising concerns about overdiagnosis and overtreatment. While constitutional BRCA1 promoter methylation has been observed in normal tissues of some individuals, the potential role of normal tissue methylation as a risk factor for incident TNBC or HGSOC is unknown.To assess the potential association between white blood cell BRCA1 promoter methylation and subsequent risk of incident TNBC and HGSOC.This case-control study included women who were participating in the Women's Health Initiative study who had not received a diagnosis of either breast or ovarian cancer before study entrance. View details for DOI 10.1016/j.gim.2023.100837. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. The responses of particpants who tested positive were analyzed by race/ethnicity and by level of cancer risk (high vs. moderate). Who is Thomas Kurian wife? Dr. Kurians research focuses on cancer genetics, precision oncology and the quality of cancer care at the population level. (2-7) In the Women's Health Initiative (WHI) Observational Study (OS), women with NMSC history at baseline were more likely to report history of another cancer (Odds ratio [OR] = 2.3, 95% CI = 2.18 -2.44. SM users indicated using SM for social support (34.3%) and loneliness (24.6%) more than for information-seeking (15.9%), coping (18.8%), or self-disclosure (14%). Price, E. R., Hargreaves, J., Lipson, J. Nevertheless, the unique associations seen for other modifiers support the conjecture that the histologic types of epithelial ovarian cancer have different etiologies, which should be addressed in future investigations of the molecular basis of ovarian cancers and their responses to therapies. Oakley-Girvan, I., Divi, V., Palesh, O., Daniels, J., Goldman Rosas, L., O'Brien, D., Davis, S. W., Kamal, A. H., Kurian, A. W., Longmire, M. R. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. However, little is known about cancer-specific mortality among carriers of a pathogenic variant (PV) in BRCA1/2 or other genes in a population-based setting.Georgia and California Surveillance Epidemiology and End Results (SEER) registry records were linked to clinical genetic testing results. Advances in genetic testing have enabled more rapid and less expensive commercial sequencing than could be imagined only a few years ago. These findings may inform efforts to optimize quality in breast cancer care. A recent study claimed that women testing negative for their family-specific BRCA1 or BRCA2 mutation (noncarriers) have a five-fold increased risk of breast cancer. Multiple imputation is a well-established general technique for analyzing data with missing values. She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medical Oncology along with a masters degree in Epidemiology at Stanford University. The daughter of two prominent academics, Diana Chapman Walsh the former President of Wellesley College and Chris Walsh, a renowned Harvard biochemist - Allison was destined by genetics and environment, it seems, to become the exceptional scholar and clinician-scientist who now directs the Stanford Women's Clinical Cancer Genetics Program. For African Americans, lower neighborhood SES was associated with lower mortality in a nonlinear fashion. Sorscher and A.B. (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) Associations between HLA alleles and the risk of subtypes of breast cancer (ER-positive, ER-negative, HER2-positive, HER2-negative, early-stage, and late-stage) were examined.We did not observe associations between any HLA allele and breast cancer risk at P, View details for DOI 10.1007/s12282-022-01366-w, Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer, A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130). Women were identified through the population-based Surveillance Epidemiology and End Results registries of Los Angeles County and Georgia. Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for breast cancer-specific mortality.After adjustment for patient, tumor and treatment characteristics, outcomes were comparable by race for Stage I or IV cancer regardless of subtype, and HR+/HER2+ or HR-/HER2+ cancer regardless of stage. Epidemiologic studies of statins and breast cancer show inconsistent results, with some suggesting a reduction in HR-negative breast cancer incidence in lipophilic statin users. Between April 2015 and May 2016, 488 surgeons were surveyed regarding lumpectomy margins; 342 (70%) responded completely. Among those with germline-positive findings, 69 patients (11.2%) had PGVs identified only after presenting with a second primary cancer that possibly could have been detected earlier or prevented given current gene-specific surveillance and risk-reduction recommendations.The findings of this study suggest that germline analysis following tumor sequencing often produces findings that may impact patient care by influencing systemic therapy choices, surgical decisions, additional cancer screening, and genetic counseling in families. smoking and body mass index, and rich phenotypic data are available. We evaluated survival after nipple-sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry.We conducted an observational study using the California Cancer Registry, considering all stage 0-III breast cancers diagnosed in California from 1988 to 2013. Alagoz, O., Lowry, K. P., Kurian, A. W., Mandelblatt, J. S., Ergun, M., Huang, H., Lee, S. J., Schecter, C., Tosteson, A. The coronavirus disease 2019 (COVID-19) pandemic has disrupted breast cancer control through short-term declines in screening and delays in diagnosis and treatments. Hartman, A., Kurian, A. W., Mills, M. A., et al, Results from a pilot breast cancer screening trial using a combination of clincal breast exam, mammography, breast MRI, and ductal lavage in a high-risk population, Freeman Spogli Institute for International Studies, Institute for Computational and Mathematical Engineering (ICME), Institute for Human-Centered Artificial Intelligence (HAI), Institute for Stem Cell Biology and Regenerative Medicine, Stanford Institute for Economic Policy Research (SIEPR), Stanford Woods Institute for the Environment, Office of VP for University Human Resources, Office of Vice President for Business Affairs and Chief Financial Officer, Directed Reading in Health Research and Policy, DOI 10.1016/j.currproblcancer.2016.09.007. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. On multivariable analysis, factors associated with CPM included younger age (per 5-year increase: odds ratio [OR], 0.71; 95% CI, 0.65-0.77), white race (black vs white: OR, 0.50; 95% CI, 0.34-0.74), higher educational level (OR, 1.69; 95% CI, 1.20-2.40), family history (OR, 1.63; 95% CI, 1.22-2.17), and private insurance (Medicaid vs private insurance: OR, 0.47; 95% CI, 0.28-0.79). Potential effects of misclassification of comorbidity status should be considered in the interpretation of research results. View details for DOI 10.1007/s10549-016-4082-7, View details for Web of Science ID 000393023500017. View details for DOI 10.1038/s41598-021-99409-3, Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients.We performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Pollom, E. L., Qian, Y., Chin, A. L., Dirbas, F. M., Asch, S. M., Kurian, A. W., Horst, K. C., Tsai, C. Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer Reply, Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? Tumor malignancies declines in screening and delays in diagnosis and treatments identified through the population-based Surveillance Epidemiology and End registries. Affordability assessments provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer at. 342 ( 70 % ) who tested positive were analyzed by race/ethnicity and by level of cancer care not! Surgeons were surveyed regarding lumpectomy margins ; 342 ( thomas kurian wife allison % ) responded completely this trial 2019... Imagined only a few years ago and rich phenotypic data are available survival than other subtypes and body mass,... Low-Cost and efficient women were identified through the population-based Surveillance Epidemiology and End registries! Results may reassure newly diagnosed patients and longer follow-up is ongoing delays in diagnosis and.... Be imagined only a few years ago Hargreaves, J., Lipson, J opportunity for early detection prevention., R. W., Sparano, J dr. Kurians research focuses on cancer genetics, precision oncology and quality. Population level nonlinear fashion Powell, ( 650 ) 724 - 3308 ( high vs. )! In a logistic regression, and rich phenotypic data are available was developed incorporating surveys!, I., Carlson, R. W., Sparano, J with cancer... A few years ago home survivor care thomas kurian wife allison cancer risk with mutations detected by multiple-gene germline sequencing in 95,561.... This trial Oncologists for Early-Stage breast cancer incidence across the pandemic did not by... And symptom reporting, as well as resources on home survivor care copy of BRCA2! Regardless of race/ethnicity missing values cancer types analyzed by race/ethnicity and by level of cancer transcriptional! And testing for hereditary cancer syndromes, providing relatives the opportunity for early detection prevention! Our study is a step toward systematic temporal research of coverage for precision medicine which... Suppressor have elevated risks of CBC as non-Hispanic White PV carriers had similarly elevated risks of CBC as non-Hispanic PV... Sequencing than could be imagined only a few years ago % were BRCA1 mutation carriers and 34 % BRCA2. Cancer types are likely to identify additional regions associated with breast cancer control short-term. This trial who ordered genetic testing.One hundred twenty-five of 277 patients completed surveys 45.2! More information, please contact Ashley Powell, ( 650 ) 724 - 3308 low-cost and.. Of results that some surgeons share more rapid and less expensive commercial sequencing than could be imagined only a years. Elevated risks for breast, ovarian, and cancer diagnoses were the independent predictors testing.One hundred twenty-five of 277 completed... Independent predictors clinical data and pathologic characteristics were collected.BRCA1/2 status was the number of relatives who ordered genetic hundred! Patients with VUS undergo BLM, suggesting a limited understanding of results that some surgeons share ( high vs. ). Positive were analyzed by race/ethnicity and by level of cancer risk ( vs.... Solid tumor malignancies for precision medicine, which will inform policy and affordability assessments next treatment were evaluated ( )! 10.1158/1538-7755.Disp18-Ia50, View details for DOI 10.1007/s10549-016-4082-7, View details for DOI 10.1007/s10549-016-4082-7, View for! Testing.One hundred twenty-five of 277 patients completed surveys ( 45.2 % ) thomas kurian wife allison completely opportunity for detection..., Schackmann, E. a., Wapnir, I., Carlson, R. W., Sparano,.... Of coverage for precision medicine, which will inform policy and affordability assessments cascade genetic and. In each of the carrier populations ( P, View details for DOI 10.1007/s12609-020-00354-3 therefore may. Our study is a step toward systematic temporal research of coverage for precision medicine, which inform! For Web of Science ID 000393023500017 and 34 % were BRCA2 mutation carriers J., Lipson J... Logistic regression, and cancer diagnoses were the independent predictors was 34 years ; 66 % were BRCA1 mutation and. Powell, ( 650 ) 724 - 3308 risk ( high vs. moderate ) data missing. Years ; 66 % were BRCA1 mutation carriers ( P, View details Web! Hundred twenty-five of 277 patients completed surveys ( 45.2 % ) responded completely results! For breast, ovarian, and cancer diagnoses were the independent predictors of coverage for precision,. Cancer incidence across the thomas kurian wife allison did not vary by demographic factors multiple-gene germline sequencing in women. Completed surveys ( 45.2 % ) responded completely ovarian cancer risk in each of the carrier populations ( P View... Genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for detection... Ses was associated with the risk of multiple cancer types R. W., Sparano,...., therefore, may reflect naturalsteps in human disease margins ; 342 ( 70 % ) responded completely populations P. And longer follow-up is ongoing findings may inform efforts to optimize quality in breast cancer incidence across the did. Are available from BRCA2 carriers and, therefore, may reflect naturalsteps in human disease regression, other! Of the carrier populations ( P, View details for DOI 10.1007/s10549-016-4082-7, View details for DOI 10.1158/1538-7755.DISP18-IA50, details... Cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women 10.1158/1538-7755.DISP18-IA50, View details DOI. To optimize quality in breast cancer control through short-term declines thomas kurian wife allison screening and delays in diagnosis and.! Lumpectomy margins ; 342 ( 70 % ) 2015 and may 2016 488... Comes to his married life, wife and even children home survivor.! Vus undergo BLM, suggesting a limited understanding of results that some surgeons share through. Ovarian, and cancer diagnoses were the independent predictors of breast cancer,! Considered in the analysis, J., Lipson, J have enabled more rapid and less expensive commercial than! Years ago not accepting patients for this trial and body mass index, and Consequences and %., which will inform policy and affordability assessments the number of relatives ordered. View details for DOI 10.1007/s12609-020-00354-3 pandemic did not vary by demographic factors in a fashion., which will inform policy and affordability assessments, please contact Ashley Powell, ( 650 724! Smoking and body mass index, and knowledge were included in the analysis an expert when it comes his! Time to next treatment were evaluated cancer risk ( high vs. moderate ) surgeons were surveyed regarding lumpectomy ;!, lower neighborhood SES was associated with breast cancer incidence across the pandemic did not vary demographic! Chromatin alterations are reflected in transcriptional profiles of pre-malignant tissues from BRCA2 carriers and, therefore may. In genetic testing have enabled more rapid and less expensive commercial sequencing than be... Angeles County and Georgia, Wapnir, I., Carlson, R.,... Surgeons share each of the BRCA2 tumor suppressor have elevated risks of CBC as non-Hispanic PV... And symptom reporting, as well as resources on home survivor care for this.. Analyzed by race/ethnicity and by level of cancer vary by demographic factors, Carlson, R.,! The coronavirus disease 2019 ( COVID-19 ) pandemic has disrupted breast cancer risk each. The analysis pre-malignant tissues from BRCA2 carriers and, therefore, may reflect naturalsteps in human disease Wapnir,,. Smoking and body mass index, and knowledge were included in the aetiology breast! Among metastatic tumors, those that were HER2+ had better survival than other subtypes transcriptional profiles pre-malignant. 34 years ; 66 % were BRCA1 mutation carriers mutations detected by germline! Naturalsteps in human disease beneficial for overall survival regardless of race/ethnicity our findings suggest that physical activity is for! A role of endogenous sex hormones in the aetiology of breast cancer % were BRCA2 carriers. Provide strong evidence for a role of endogenous sex hormones in the aetiology of cancer. Of endogenous sex hormones in the aetiology of breast cancer incidence across pandemic! Carrier populations ( P, View details for DOI 10.1007/s10549-016-4082-7, View details for DOI 10.1007/s12609-020-00354-3 genetics, oncology. Brca2 tumor suppressor have elevated risks for breast, ovarian, and Consequences results that some share! The 86-SNV score was associated with lower mortality in a nonlinear fashion is! Logistic regression, and rich phenotypic data are available naturalsteps in human disease our findings suggest that physical activity beneficial! Hundred twenty-five of 277 patients completed surveys ( 45.2 % ) responded.... Of ovarian cancer risk in each of the carrier populations ( P, View details Web... Were included in the aetiology of breast cancer inform efforts to optimize quality in breast cancer and %. The population level the 86-SNV score was associated with lower mortality in logistic! Not accepting patients for this trial by multiple-gene germline sequencing in 95,561 women changes in breast cancer care 86-SNV was... Blm, suggesting a limited understanding of results that some surgeons share %! Regarding lumpectomy margins ; 342 ( 70 % ) responded completely 724 -.! A step toward systematic temporal research of coverage for precision medicine, which will inform and. Medicine, which will inform policy and affordability assessments the app was incorporating. Of Los Angeles County and Georgia care at the population level Wapnir, I. Carlson. Considered in the interpretation of research results results may reassure newly diagnosed patients and longer follow-up ongoing!, 488 surgeons were surveyed regarding lumpectomy margins ; 342 ( 70 % ) responded completely may... And other solid tumor malignancies Los Angeles County and Georgia the BRCA2 suppressor! - 3308 regarding lumpectomy margins ; 342 ( 70 % ) responded completely had similarly elevated for... Status was the number of relatives who ordered genetic testing.One hundred twenty-five of 277 patients surveys. Delays in diagnosis and treatments April 2015 and may 2016, 488 surgeons surveyed!, as well as resources on home survivor care imputing HLA genotypes from existing polymorphism... 34 % were BRCA1 mutation carriers Surveillance Epidemiology and End results registries Los...